Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) (TA960)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2024
Risdiplam for treating spinal muscular atrophy (TA755)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 15 December 2023Published: 16 December 2021
Tofacitinib for treating active ankylosing spondylitis (TA920)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 October 2023
Bimekizumab for treating axial spondyloarthritis (TA918)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2023
Upadacitinib for treating active ankylosing spondylitis (TA829)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 September 2022
Nusinersen for treating spinal muscular atrophy (TA588)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2019
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 February 2016
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013
Omaveloxolone for treating Friedreich’s ataxia in people 16 years and over ID6423Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 August 2025
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Bimekizumab for treating ankylosing spondylitis TS ID 10334Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Troriluzole for spinocerebellar ataxia ID 6456Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TS ID 12048]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC